What BMI do you need for GLP-1 medication?

A BMI of 27 or higher is the standard clinical threshold used by providers to assess GLP-1 medication candidacy. A BMI of 27–29.9 typically requires at least one weight-related health condition. A BMI of 30 or above generally qualifies without an additional condition. A licensed provider makes the final eligibility determination based on your full health profile.

How much weight can you lose on semaglutide?

The STEP-1 clinical trial (Wilding et al., NEJM 2021) showed an average body weight loss of 14.9% with semaglutide over 68 weeks. Individual results vary based on starting weight, adherence, diet, activity level, and metabolic response.

How much weight can you lose on tirzepatide?

The SURMOUNT-1 clinical trial (Jastreboff et al., NEJM 2022) showed an average body weight loss of 22.5% with tirzepatide at the highest dose over 72 weeks. Individual results vary based on starting weight, adherence, diet, activity level, and metabolic response.

Is BMI an accurate measure of health?

BMI is a general screening tool calculated from height and weight. It does not account for muscle mass, bone density, or fat distribution. It is a starting point for clinical assessment, not a definitive measure of health or eligibility. A licensed provider reviews your complete health picture before any treatment decision.

How is BMI calculated?

BMI is calculated by dividing weight in kilograms by height in meters squared (kg/m²). In imperial units: BMI = (weight in pounds × 703) ÷ (height in inches²). A BMI under 18.5 is considered underweight, 18.5–24.9 is normal, 25–29.9 is overweight, and 30 or above is classified as obese.

GLP-1 Tools

BMI & Weight Loss Estimator

Enter your details once. See your BMI and your personalized weight loss estimate — synced together in one flow.

Your Details

BMI Result

Weight Loss Estimate

Step 1 of 3

Enter your height and weight

Enter your details once — we'll calculate your BMI and weight loss estimate together.

Height

Required

Weight

lbs

Required

Live BMI estimate --

Step 2 of 3 · BMI Result

Your BMI

BMI

Step 3 of 3 · Weight Loss Estimate

Your GLP-1 estimate

Based on published clinical trial data. Drag the slider to explore a range of outcomes.

Estimated body weight loss 15%

Adjust estimate: 15% body weight

5% (conservative)25% (max trial avg)

Ready to get started?

Complete a free health intake. A licensed Ondra provider reviews your profile and responds within 24 hours. No in-person visit required in most states.

Start My Free Intake

No commitment · Only charged if treatment is approved by your provider

About these tools

What each number means and where the estimates come from.

What is BMI?

Body Mass Index is a screening tool calculated from height and weight. It's the primary threshold providers use to assess GLP-1 candidacy — a BMI of 27 or higher is the standard clinical range.

Where do the estimates come from?

The weight loss percentages are based on average outcomes from the STEP-1 trial (semaglutide, −14.9%, Wilding et al. 2021 NEJM) and the SURMOUNT-1 trial (tirzepatide, −22.5%, Jastreboff et al. 2022 NEJM).

BMI is a starting point, not a verdict

BMI doesn't account for muscle mass, bone density, or fat distribution. A licensed provider reviews your complete health picture — no calculator determines your eligibility.

Provider always makes the final call

These tools are for informational purposes only. A licensed Ondra provider reviews your full health intake before any treatment decision is made. Individual results vary significantly.

Disclaimer: BMI is a general screening tool and does not constitute a medical assessment or diagnosis. Weight loss estimates are based on average outcomes from published clinical trials and are not a guarantee of personal results. Individual results vary based on starting weight, adherence, activity level, diet, and metabolic response. This tool is for informational purposes only and does not constitute medical advice. GLP-1 eligibility is determined by a licensed healthcare provider. Consult a licensed provider before starting any weight loss medication. Trial references: Wilding et al. (2021), NEJM — STEP-1 (semaglutide). Jastreboff et al. (2022), NEJM — SURMOUNT-1 (tirzepatide).